Jarom Heijmans
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jarom Heijmans has a total of 206 co-authors. Here are the top co-authors by number of shared publications:
Vanesa Muncan
Affiliation Amsterdam UMC, University of Amsterdam, department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands
5 shared publications- Erfan Nur
Department of Hematology, Amsterdam University Medical Center, University of Amsterdam, Amsterdam, The Netherlands
3 shared publications Inger S Nijhof
Department of Hematology, Amsterdam UMC, VU University , Amsterdam
3 shared publicationsWouter L. Smit
Affiliations Amsterdam UMC, University of Amsterdam, department of Gastroenterology and Hepatology, Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands, Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, The Netherlands
3 shared publicationsAbraham Goorhuis
Department of Infectious Diseases, Amsterdam UMC Location University of Amsterdam , Amsterdam , The Netherlands
2 shared publicationsArnon P Kater
Department of Hematology, Amsterdam UMC Location University of Amsterdam , Amsterdam , The Netherlands
2 shared publications
Latest Publications
- Open Access
- 29 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Potential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes
Background and Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have anti-inflammatory effects in experimental studies, but their mechanism of action in humans remains unclear. This study characterized the cardiovascular–haematopoietic axis in individuals with T2D receiving semaglutide, as a potential mediator of GLP-1RA cardioprotective properties. Methods: In 16 individuals with T2D [63.2 ± 6.1 years, 37.5% female, weight 82.3 ± 15.3 kg, body mass index (BMI) 28.33 ± 3.5 kg/m2, LDL cholesterol 2.2 ± 0.9 mmol/L, glycated haemoglobin (HbA1c) 78.1 ± 13.1 mmol/mol, high-sensitivity C-reactive protein (hsCRP) 1.9 (1.2, 5.8) mg/L], blood and sternal bone marrow aspirates (subset, n = 14) were collected at baseline and after 6 months of semaglutide ≤2.0 mg weekly. Circulating monocytes and haematopoietic precursors were quantified by flow cytometry, plasma cytokines using an nELISA™ assay (Nomic Bio) and inflammatory macrophages in coronary arteries, bone marrow, and spleen by gallium-68–labelled DOTA-(Tyr3)-octreotate (68Ga-DOTATATE) positron emission tomography-computed tomography scans. Results: After 6 months of semaglutide, significant reductions in HbA1c (−21.1 mmol/mol, P < .0001), weight (−6.7 kg, P < .001), BMI (−2.5 kg/m2, P < .001), and hsCRP (−1.0 mg/L, P = .005) were observed. Circulating CD16+ monocytes were markedly lower (−18.8%, P = .034), with increased bone marrow retention correlating with weight loss, alongside reductions in interleukin-1 receptor antagonist, leptin, E-selectin, intercellular adhesion molecule-1 (ICAM-1), C-C motif chemokine ligand 2, C-C motif chemokine ligand 11, and C-X-C motif chemokine ligand 13. Gallium-68–labelled DOTA-(Tyr3)-octreotate PET-CT showed lower bone marrow uptake (−17.5%, P = .037), but not in spleen or coronary arteries. Conclusions: Semaglutide in T2D potentially reduces circulating inflammatory monocytes, increases bone marrow retention, and lowers markers of endothelial inflammation, with no reduction in coronary artery inflammatory macrophages. Semaglutide is associated with lower bone marrow 68Ga-DOTATATE uptake, which may relate to anti-inflammatory effects relevant to CVD risk.
- 29 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal
Open AccessPotential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes
Background and Aims: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have anti-inflammatory effects in experimental studies, but their mechanism of action in humans remains unclear. This study characterized the cardiovascular–haematopoietic axis in individuals with T2D receiving semaglutide, as a potential mediator of GLP-1RA cardioprotective properties. Methods: In 16 individuals with T2D [63.2 ± 6.1 years, 37.5% female, weight 82.3 ± 15.3 kg, body mass index (BMI) 28.33 ± 3.5 kg/m2, LDL cholesterol 2.2 ± 0.9 mmol/L, glycated haemoglobin (HbA1c) 78.1 ± 13.1 mmol/mol, high-sensitivity C-reactive protein (hsCRP) 1.9 (1.2, 5.8) mg/L], blood and sternal bone marrow aspirates (subset, n = 14) were collected at baseline and after 6 months of semaglutide ≤2.0 mg weekly. Circulating monocytes and haematopoietic precursors were quantified by flow cytometry, plasma cytokines using an nELISA™ assay (Nomic Bio) and inflammatory macrophages in coronary arteries, bone marrow, and spleen by gallium-68–labelled DOTA-(Tyr3)-octreotate (68Ga-DOTATATE) positron emission tomography-computed tomography scans. Results: After 6 months of semaglutide, significant reductions in HbA1c (−21.1 mmol/mol, P < .0001), weight (−6.7 kg, P < .001), BMI (−2.5 kg/m2, P < .001), and hsCRP (−1.0 mg/L, P = .005) were observed. Circulating CD16+ monocytes were markedly lower (−18.8%, P = .034), with increased bone marrow retention correlating with weight loss, alongside reductions in interleukin-1 receptor antagonist, leptin, E-selectin, intercellular adhesion molecule-1 (ICAM-1), C-C motif chemokine ligand 2, C-C motif chemokine ligand 11, and C-X-C motif chemokine ligand 13. Gallium-68–labelled DOTA-(Tyr3)-octreotate PET-CT showed lower bone marrow uptake (−17.5%, P = .037), but not in spleen or coronary arteries. Conclusions: Semaglutide in T2D potentially reduces circulating inflammatory monocytes, increases bone marrow retention, and lowers markers of endothelial inflammation, with no reduction in coronary artery inflammatory macrophages. Semaglutide is associated with lower bone marrow 68Ga-DOTATATE uptake, which may relate to anti-inflammatory effects relevant to CVD risk.
- Open Access
- 24 August 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Association between severe RSV pneumonia and invasive pulmonary aspergillosis
- 24 August 2026
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 26 (1)
Open AccessAssociation between severe RSV pneumonia and invasive pulmonary aspergillosis
- Open Access
- 9 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0344161
Reduced levels of mitochondrial ribosomal protein MRPL54 does not alter Apc related adenoma formation
Reprogramming of energy metabolism is one of the hallmarks of cancer cells and mutations that modify wild type intestinal cells to colon carcinomas increases cellular energy expenditure. Mitochondria are the main site for ATP production in (cancer) cells and disrupting their function results in impaired tumor forming efficacy. The mitochondrial ribosomal proteins (MRPs) constitute the ribosome specifically in mitochondria, and as such are crucial for the translation process of the electron transport chain complex subunits. We hence aimed to explore the consequence of reduced MRP expression on adenomagensis and investigate this in a genetic mouse model with bodywide heterozygosity for Mrpl54 . We show that Mrpl54 heterozygosity does not alter adenoma formation, intestinal proliferation or apoptosis in a heterozygous Apc model. Furthermore, diminished Mrpl54 expression did not decrease stemness or global parameters of metabolism in colorectal cancer cell lines.
- 9 March 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (3) , e0344161
Open AccessReduced levels of mitochondrial ribosomal protein MRPL54 does not alter Apc related adenoma formation
Reprogramming of energy metabolism is one of the hallmarks of cancer cells and mutations that modify wild type intestinal cells to colon carcinomas increases cellular energy expenditure. Mitochondria are the main site for ATP production in (cancer) cells and disrupting their function results in impaired tumor forming efficacy. The mitochondrial ribosomal proteins (MRPs) constitute the ribosome specifically in mitochondria, and as such are crucial for the translation process of the electron transport chain complex subunits. We hence aimed to explore the consequence of reduced MRP expression on adenomagensis and investigate this in a genetic mouse model with bodywide heterozygosity for Mrpl54 . We show that Mrpl54 heterozygosity does not alter adenoma formation, intestinal proliferation or apoptosis in a heterozygous Apc model. Furthermore, diminished Mrpl54 expression did not decrease stemness or global parameters of metabolism in colorectal cancer cell lines.
- Open Access
- 14 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e363-e372
COVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study
Background: In patients with hematologic malignancies, COVID-19 vaccine effectiveness is unknown and determinants of severe COVID-19 lack granularity. Methods: To identify determinants of SARS-CoV-2 infection outcome we conducted a population-based, nationwide cohort study, including all adult Dutch residents who tested positive for SARS-CoV-2 between 1 June 2020, and 31 March 2022. Individuals were classified as having a (history of) hematologic malignancy, solid malignancy, or no malignancies. Primary outcome was severe COVID-19, defined as COVID-19-related hospitalization or death following first SARS-CoV-2 infection. Results: Among 4 649 341 included individuals, those with hematologic malignancies were at highest risk of severe COVID-19. Vaccine effectiveness against severe COVID-19 in patients with hematologic malignancies was up to 74% (95% CI, 60% to 83%), depending on the SARS-CoV-2 variant period, the number of received vaccinations, and the time interval since vaccination. Risk of severe COVID-19 was highest for patients with recently diagnosed hematologic malignancies and declined over time, except for patients with chronic hematologic malignancies. Risk of severe COVID-19 tended to be higher in patients on tumor-specific treatment such as CD38 and CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors. Conclusions: COVID-19 vaccination lowered the risk of severe COVID-19 in SARS-CoV-2-infected patients with hematologic malignancies, although these patients remained at elevated risk compared with others. Determinants of severe COVID-19 included type of malignancy, time interval between malignancy diagnosis and SARS-CoV-2 infection, and treatment. These data can guide healthcare professionals in designing additional prevention and therapeutic strategies against respiratory virus infections for patients with hematologic malignancies.
- 14 October 2025
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 233 (2) , e363-e372
Open AccessCOVID-19 Vaccine Effectiveness in Patients With Hematologic Malignancies: A Nationwide Cohort Study
Background: In patients with hematologic malignancies, COVID-19 vaccine effectiveness is unknown and determinants of severe COVID-19 lack granularity. Methods: To identify determinants of SARS-CoV-2 infection outcome we conducted a population-based, nationwide cohort study, including all adult Dutch residents who tested positive for SARS-CoV-2 between 1 June 2020, and 31 March 2022. Individuals were classified as having a (history of) hematologic malignancy, solid malignancy, or no malignancies. Primary outcome was severe COVID-19, defined as COVID-19-related hospitalization or death following first SARS-CoV-2 infection. Results: Among 4 649 341 included individuals, those with hematologic malignancies were at highest risk of severe COVID-19. Vaccine effectiveness against severe COVID-19 in patients with hematologic malignancies was up to 74% (95% CI, 60% to 83%), depending on the SARS-CoV-2 variant period, the number of received vaccinations, and the time interval since vaccination. Risk of severe COVID-19 was highest for patients with recently diagnosed hematologic malignancies and declined over time, except for patients with chronic hematologic malignancies. Risk of severe COVID-19 tended to be higher in patients on tumor-specific treatment such as CD38 and CD20 antibodies, proteasome inhibitors, and protein kinase inhibitors. Conclusions: COVID-19 vaccination lowered the risk of severe COVID-19 in SARS-CoV-2-infected patients with hematologic malignancies, although these patients remained at elevated risk compared with others. Determinants of severe COVID-19 included type of malignancy, time interval between malignancy diagnosis and SARS-CoV-2 infection, and treatment. These data can guide healthcare professionals in designing additional prevention and therapeutic strategies against respiratory virus infections for patients with hematologic malignancies.
- Open Access
- 3 September 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (5)
Impact of an antimicrobial stewardship bundle on the outcome of high-risk neutropenic patients with fever: a pre-post study
Background: Rapid antibiotic initiation is essential for managing potential infections following chemotherapy-induced neutropenia. However, excessive use of broad-spectrum antibiotics should be avoided. Implementing antimicrobial stewardship (AMS) in haematology units is challenging due to high infection-related risks, and data on interventions remain scarce. This study aimed to evaluate the safety of an AMS bundle on a haematology ward. Methods: A prospective cohort study was conducted at a tertiary care centre among patients with high-risk (≥7 days) neutropenia. The AMS bundle consisted of replacing empirical meropenem with ceftazidime, and shortening treatment duration to 2 days in case of defervescence and negative blood cultures. Data on ICU admission, all-cause mortality, antimicrobial use and microorganisms identified were compared with a (retrospective) pre-intervention cohort. Results: A total of 396 patients were included (206 pre-intervention, 190 post-intervention). Allogeneic stem cell transplantations increased from 21% pre-intervention to 37% post-intervention. There was no statistical difference in the adjusted composite endpoint of ICU admission and all-cause mortality [adjusted HR (aHR) 1.46; 95% CI, 0.76–2.81; P = 0.26]. Pre-intervention, meropenem was prescribed in 99% of patients, which shifted to ceftazidime in 78% post-intervention. Median antibiotic treatment duration decreased from 8.0 to 5.0 days (P < 0.001), and empirical antibiotic consumption decreased from 12 to 8 days of therapy per patient (P < 0.001). Bloodstream infections with Candida spp. decreased from 17 pre-intervention to 5 post-intervention (P = 0.03). Conclusions: The AMS bundle led to a shift towards narrower-spectrum antibiotics, and reduced treatment duration and overall antibiotic use without a significant impact on the primary safety outcome. The intervention was accompanied by a declining trend in candidaemia incidence.
- 3 September 2025
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 7 (5)
Open AccessImpact of an antimicrobial stewardship bundle on the outcome of high-risk neutropenic patients with fever: a pre-post study
Background: Rapid antibiotic initiation is essential for managing potential infections following chemotherapy-induced neutropenia. However, excessive use of broad-spectrum antibiotics should be avoided. Implementing antimicrobial stewardship (AMS) in haematology units is challenging due to high infection-related risks, and data on interventions remain scarce. This study aimed to evaluate the safety of an AMS bundle on a haematology ward. Methods: A prospective cohort study was conducted at a tertiary care centre among patients with high-risk (≥7 days) neutropenia. The AMS bundle consisted of replacing empirical meropenem with ceftazidime, and shortening treatment duration to 2 days in case of defervescence and negative blood cultures. Data on ICU admission, all-cause mortality, antimicrobial use and microorganisms identified were compared with a (retrospective) pre-intervention cohort. Results: A total of 396 patients were included (206 pre-intervention, 190 post-intervention). Allogeneic stem cell transplantations increased from 21% pre-intervention to 37% post-intervention. There was no statistical difference in the adjusted composite endpoint of ICU admission and all-cause mortality [adjusted HR (aHR) 1.46; 95% CI, 0.76–2.81; P = 0.26]. Pre-intervention, meropenem was prescribed in 99% of patients, which shifted to ceftazidime in 78% post-intervention. Median antibiotic treatment duration decreased from 8.0 to 5.0 days (P < 0.001), and empirical antibiotic consumption decreased from 12 to 8 days of therapy per patient (P < 0.001). Bloodstream infections with Candida spp. decreased from 17 pre-intervention to 5 post-intervention (P = 0.03). Conclusions: The AMS bundle led to a shift towards narrower-spectrum antibiotics, and reduced treatment duration and overall antibiotic use without a significant impact on the primary safety outcome. The intervention was accompanied by a declining trend in candidaemia incidence.
- 26 December 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (5) , 736-738
Proteinuria Remission in Recurrent FSGS after Autologous Stem Cell Transplantation
An abstract is unavailable. This article is available as a PDF only.
- 26 December 2024
- Published by Wolters Kluwer Health in Clinical Journal of the American Society of Nephrology
- Vol. 20 (5) , 736-738
Proteinuria Remission in Recurrent FSGS after Autologous Stem Cell Transplantation
An abstract is unavailable. This article is available as a PDF only.
- 14 February 2024
- Published by Elsevier in Cancer Letters
- Vol. 587, 216678
ER stress and the unfolded protein response in gastrointestinal stem cells and carcinogenesis
- 14 February 2024
- Published by Elsevier in Cancer Letters
- Vol. 587, 216678
ER stress and the unfolded protein response in gastrointestinal stem cells and carcinogenesis
- Open Access
- 19 October 2023
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 180, 105264
Correctly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trial
- 19 October 2023
- Published by Elsevier in International Journal of Medical Informatics
- Vol. 180, 105264
Open AccessCorrectly structured problem lists lead to better and faster clinical decision-making in electronic health records compared to non-curated problem lists: A single-blinded crossover randomized controlled trial
- Open Access
- 29 August 2023
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (11) , e202301912
Grp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis
In development of colorectal cancer, mutations inAPCare often followed by mutations in oncogeneKRAS. The latter changes cellular metabolism and is associated with the Warburg phenomenon. Glucose-regulated protein 78 (Grp78) is an important regulator of the protein-folding machinery, involved in processing and localization of transmembrane proteins. We hypothesize that targetingGrp78inApcandKras(AK)-mutant intestines interferes with the metabolic phenotype imposed byKrasmutations. In mice with intestinal epithelial mutations inApc,KrasG12Dand heterozygosity forGrp78(AK-Grp78HET) adenoma number and size is decreased compared withAK-Grp78WTmice. Organoids fromAK-Grp78WTmice exhibited a glycolysis metabolism which was completely rescued byGrp78heterozygosity. Expression and correct localization of glucose transporter GLUT1 was diminished inAK-Grp78HETcells. GLUT1 inhibition restrained the increased growth observed inAK-mutant organoids, whereasAK-Grp78HETorganoids were unaffected. We identifyGrp78as a critical factor inKras-mutated adenomagenesis. This can be attributed to a critical role forGrp78in GLUT1 expression and localization, targeting glycolysis and the Warburg effect.
- 29 August 2023
- Published by Life Science Alliance, LLC in Life Science Alliance
- Vol. 6 (11) , e202301912
Open AccessGrp78 is required for intestinal Kras-dependent glycolysis proliferation and adenomagenesis
In development of colorectal cancer, mutations inAPCare often followed by mutations in oncogeneKRAS. The latter changes cellular metabolism and is associated with the Warburg phenomenon. Glucose-regulated protein 78 (Grp78) is an important regulator of the protein-folding machinery, involved in processing and localization of transmembrane proteins. We hypothesize that targetingGrp78inApcandKras(AK)-mutant intestines interferes with the metabolic phenotype imposed byKrasmutations. In mice with intestinal epithelial mutations inApc,KrasG12Dand heterozygosity forGrp78(AK-Grp78HET) adenoma number and size is decreased compared withAK-Grp78WTmice. Organoids fromAK-Grp78WTmice exhibited a glycolysis metabolism which was completely rescued byGrp78heterozygosity. Expression and correct localization of glucose transporter GLUT1 was diminished inAK-Grp78HETcells. GLUT1 inhibition restrained the increased growth observed inAK-mutant organoids, whereasAK-Grp78HETorganoids were unaffected. We identifyGrp78as a critical factor inKras-mutated adenomagenesis. This can be attributed to a critical role forGrp78in GLUT1 expression and localization, targeting glycolysis and the Warburg effect.
- Open Access
- 2 November 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (12) , e16194
Intestinal Apc‐inactivation induces HSP25 dependency
The majority of colorectal cancers (CRCs) present with early mutations in tumor suppressor gene APC. APC mutations result in oncogenic activation of the Wnt pathway, which is associated with hyperproliferation, cytoskeletal remodeling, and a global increase in mRNA translation. To compensate for the increased biosynthetic demand, cancer cells critically depend on protein chaperones to maintain proteostasis, although their function in CRC remains largely unexplored. In order to investigate the role of molecular chaperones in driving CRC initiation, we captured the transcriptomic profiles of murine wild type and Apc‐mutant organoids during active transformation. We discovered a strong transcriptional upregulation of Hspb1, which encodes small heat shock protein 25 (HSP25). We reveal an indispensable role for HSP25 in facilitating Apc‐driven transformation, using both in vitro organoid cultures and mouse models, and demonstrate that chemical inhibition of HSP25 using brivudine reduces the development of premalignant adenomas. These findings uncover a hitherto unknown vulnerability in intestinal transformation that could be exploited for the development of chemopreventive strategies in high‐risk individuals.
- 2 November 2022
- Published by Springer Nature in EMBO Molecular Medicine
- Vol. 14 (12) , e16194
Open AccessIntestinal Apc‐inactivation induces HSP25 dependency
The majority of colorectal cancers (CRCs) present with early mutations in tumor suppressor gene APC. APC mutations result in oncogenic activation of the Wnt pathway, which is associated with hyperproliferation, cytoskeletal remodeling, and a global increase in mRNA translation. To compensate for the increased biosynthetic demand, cancer cells critically depend on protein chaperones to maintain proteostasis, although their function in CRC remains largely unexplored. In order to investigate the role of molecular chaperones in driving CRC initiation, we captured the transcriptomic profiles of murine wild type and Apc‐mutant organoids during active transformation. We discovered a strong transcriptional upregulation of Hspb1, which encodes small heat shock protein 25 (HSP25). We reveal an indispensable role for HSP25 in facilitating Apc‐driven transformation, using both in vitro organoid cultures and mouse models, and demonstrate that chemical inhibition of HSP25 using brivudine reduces the development of premalignant adenomas. These findings uncover a hitherto unknown vulnerability in intestinal transformation that could be exploited for the development of chemopreventive strategies in high‐risk individuals.